Results 301 to 310 of about 95,577 (390)

Positron Emission Tomography Imaging in Clinical Trials for Parkinson's Disease: Applications of Metabolic Brain Network Approach

Movement Disorders, EarlyView.
ABSTRACT Neuroimaging with positron emission tomography (PET) has been instrumental in elucidating neurobiological mechanisms behind therapeutical trials in Parkinson's disease (PD). A variety of medical and neurosurgical interventions have been evaluated using many radioligands that reveal molecular basis for target engagement and brain responses in ...
Vijay Dhawan, Shichun Peng, Phoebe G. Spetsieris, David Eidelberg, Yilong Ma   +4 more
wiley   +1 more source

Complications associated with intestinal infusion therapies in patients with Parkinson's disease: a single-center retrospective study and 15-year experience. [PDF]

Front Neurol
Straka I, Andre Z, Kosutzka Z, Gmitterova K, Stevove M, Durkovicova Z, Juricek R, Valkovic P, Minar M.   +8 more
europepmc   +1 more source

Peripheral Mononuclear Cell Mitochondrial Function Associates with T‐Cell Cytokines in Parkinson's Disease

Movement Disorders, EarlyView.
Abstract Background Parkinson's disease (PD) is the most common neurodegenerative movement disorder and one of the world's fastest‐growing neurological diseases. Although the exact causes of PD are unknown, mitochondrial dysfunction and inflammation may have significant roles in disease progression.
Fatima Afaar, Priscilla Youssef, Jasmin Galper, Michelle Chua, Glenda M. Halliday, Simon J.G. Lewis, Nicolas Dzamko   +6 more
wiley   +1 more source

Association between the use of levodopa/carbidopa, Alzheimer's disease biomarkers, and cognitive decline among participants in the National Alzheimer's Coordinating Center Uniform Data Set. [PDF]

Alzheimers Dement
Sárkány Z, Damásio J, Macedo-Ribeiro S, Martins PM.   +3 more
europepmc   +1 more source

Retinal Thickness in Patients with Parkinson's Disease and Dopa Responsive Dystonia-Is There Any Difference? [PDF]

Biomedicines
Svetel M, Marić G, Božić M, Lazić U, Milovanović A, Jakšić J, Petrović I, Dimitrijević A, Knežević M, Pekmezović T.   +9 more
europepmc   +1 more source

EFNB3 Frameshift Variant in Weimaraner Dogs with a Condition Resembling a Congenital Mirror Movement Disorder

Movement Disorders, EarlyView.
ABSTRACT Background Congenital mirror movement disorders (CMMs) are clinically and genetically heterogeneous in human patients. CMMs have not been documented to occur spontaneously in animals. Objective The objective of this work was to document the first case of CMMs spontaneously occurring in Weimaraner dogs and to identify the underlying genetic ...
Cleo Schwarz, Florian Bartenschlager, Olivia Kershaw, Judith Braun, Julien Guevar, Vidhya Jagannathan, Jörg T. Epplen, Wencke Reineking, Wolfgang Baumgärtner, Kailash P. Bhatia, Achim D. Gruber, Tosso Leeb   +11 more
wiley   +1 more source

Microstructural Changes in the Tuberal Hypothalamus Correlate with Daytime Sleepiness in Lewy Body Disorders

Movement Disorders, EarlyView.
Abstract Background Excessive daytime sleepiness (EDS) is a disabling symptom of Lewy body disorders (LBD). The hypothalamus is a key sleep–wake regulator and is involved in Lewy pathology, but its contribution to EDS in LBD remains unclear. Objectives To use diffusion‐weighted magnetic resonance imaging (MRI) to detect hypothalamic microstructure and ...
Jesse S. Cohen, Hamsanandini Radhakrishnan, Christopher A. Olm, Sandhitsu R. Das, Philip A. Cook, David A. Wolk, Daniel Weintraub, David J. Irwin, Corey T. McMillan   +8 more
wiley   +1 more source

Genome-scale metabolic model-guided systematic framework for designing customized live biotherapeutic products. [PDF]

NPJ Syst Biol Appl
Lee YQ, Choi YM, Park SY, Kim SK, Lee M, Kim D, Koduru L, Lakshmanan M, Jung S, Kim MJ, Choe YH, Lee DY.   +11 more
europepmc   +1 more source

Early‐Onset Movement Disorder Syndrome Caused by Biallelic Variants in PDE1B Encoding Phosphodiesterase 1B

Movement Disorders, EarlyView.
Abstract Background Breakdown of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) in basal ganglia cells through hydrolysis of diesteric bonds, primarily by PDE10A and PDE1B, is essential for normal human movement. While biallelic loss‐of‐function variants in PDE10A are known to cause hyperkinetic movement disorders, the ...
Tomer Poleg, Noam Hadar, Eyal Kristal, Nicola Y. Roberts, Vadim Dolgin, Ilana Aminov, Amit Safran, Nadav Agam, Matan Jean, Ofek Freund, Eamonn G. Sheridan, James A. Poulter, Michelle L. Thompson, Yusra Algoos, Salma Al‐Qahtani, Lama AlAbdi, Sateesh Maddirevula, Verity Hartill, Henry Houlden, Reza Maroofian, Amit Nahum, Ohad S. Birk   +21 more
wiley   +1 more source